SEC Comment Letter 0000000000-24-005322 to Bio Green Med Solution, Inc. (BGMS)
Bio Green Med Solution, Inc.
Date: May 10, 2024 · CIK: 0001130166 · Accession: 0000000000-24-005322
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-279157
Letter
United States securities and exchange commission logo May 10, 2024 Paul McBarron Chief Financial Officer and Chief Operating Officer Cyclacel Pharmaceuticals, Inc. 200 Connell Drive, Suite 1500 Berkeley Heights, NJ 07922 Re:Cyclacel Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed May 6, 2024 File No. 333-279157 Dear Paul McBarron: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tamika Sheppard at 202-551-8346 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jeffrey P. Shultz
Show Raw Text
United States securities and exchange commission logo
May 10, 2024
Paul McBarron
Chief Financial Officer and Chief Operating Officer
Cyclacel Pharmaceuticals, Inc.
200 Connell Drive, Suite 1500
Berkeley Heights, NJ 07922
Re:Cyclacel Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed May 6, 2024
File No. 333-279157
Dear Paul McBarron:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tamika Sheppard at 202-551-8346 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jeffrey P. Shultz